Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Significant Decline in Short Interest

Astria Therapeutics, Inc. (NASDAQ:ATXS) was the recipient of a large decrease in short interest in the month of September. As of September 30th, there was short interest totalling 3,470,000 shares, a decrease of 9.2% from the September 15th total of 3,820,000 shares. Based on an average trading volume of 381,000 shares, the days-to-cover ratio is presently 9.1 days. Approximately 7.3% of the company’s stock are sold short.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers lifted its stake in Astria Therapeutics by 4.1% in the second quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company’s stock valued at $595,000 after buying an additional 2,556 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in Astria Therapeutics by 135.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after purchasing an additional 2,861 shares during the last quarter. Quest Partners LLC boosted its stake in Astria Therapeutics by 3,310.6% during the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 3,112 shares during the period. American International Group Inc. grew its position in Astria Therapeutics by 49.4% in the 1st quarter. American International Group Inc. now owns 24,565 shares of the biotechnology company’s stock worth $346,000 after purchasing an additional 8,122 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Astria Therapeutics by 6.9% in the second quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company’s stock valued at $1,266,000 after purchasing an additional 8,965 shares during the period. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Stock Performance

Astria Therapeutics stock opened at $11.56 on Thursday. Astria Therapeutics has a 1 year low of $4.26 and a 1 year high of $16.90. The firm’s 50-day moving average is $11.38 and its 200-day moving average is $10.50. The company has a market cap of $634.79 million, a P/E ratio of -4.98 and a beta of 0.71.

Astria Therapeutics (NASDAQ:ATXS) last issued its earnings results on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). As a group, sell-side analysts predict that Astria Therapeutics will post -1.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ATXS. Oppenheimer boosted their target price on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 13th. TD Cowen assumed coverage on shares of Astria Therapeutics in a research report on Monday, July 29th. They issued a “buy” rating and a $35.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research report on Friday, September 27th. Wedbush reaffirmed an “outperform” rating and issued a $22.00 price target on shares of Astria Therapeutics in a report on Tuesday, August 13th. Finally, Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $25.20.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.